Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 18/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 12/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22774941 | 1.00 | GRIN2B (0.41) | GRIN2BKCNH2GRIN1TRPA1 | |
| SCHEMBL22774734 | 0.86 | GRIN2B (0.43) | GRIN2BKCNH2GRIN1TRPA1 | |
| SCHEMBL22771414 | 0.84 | KCNH2 (0.51) | GRIN2BKCNH2GRIN1 | |
| SCHEMBL29901458 | 0.76 | GRIN2B (0.45) | GRIN2BKCNH2GRIN1TRPA1 | |
| SCHEMBL22775318 | 0.76 | GRIN2B (0.45) | GRIN2BKCNH2GRIN1 | |
| SCHEMBL22771417 | 0.74 | GRIN2B (0.51) | GRIN2BKCNH2GRIN1 | |
| SCHEMBL30133031 | 0.72 | TRPA1 (0.53) | GRIN2BGRIN1TRPA1 | |
| SCHEMBL29901531 | 0.71 | GRIN2B (0.46) | GRIN2BKCNH2GRIN1 | |
| SCHEMBL22775262 | 0.69 | GRIN2B (0.46) | GRIN2BKCNH2GRIN1 | |
| SCHEMBL29901513 | 0.69 | GRIN2B (0.44) | GRIN2BGRIN1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230045960-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-16 | — | — | US | disclosed |
| US-20220274984-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045960-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | GRIN2B 1/4885KCNH2 2725/4885GRIN1 6/4885 |
| US-20220274984-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | GRIN2B 1/4885KCNH2 2725/4885GRIN1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.